

QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)

Monday, June 27, 2022, at 9 am CT

Call Summary

In attendance

Robert deKemp, PhD (Co-Chair)

Jonathan B. Moody, PhD (Co-Chair)

Martin Lodge, PhD

Nancy Obuchowski, PhD

RSNA Staff

Joe Koudelik

Susan Stanfa

Moderator: Dr. deKemp

The following topics were discussed:

- Platform for working on the Profile asynchronously, e.g., GitHub vs. Google Docs, etc.
- Review of Profile-writing progress on Section 3.6.2 specification tables
- Profile focus: clinical practice vs. clinical trials
- Site accreditation requirements
- Checklist Actor certification requirements, including physicians, physicists, and technologists
- Phantom requirements

Decisions / Action items:

- Need to identify the Profile's target audience, i.e., clinical practice and/or clinical trials
- Radiopharmaceutical infusion specifications to be added once more data are available
- It will be important to highlight issue with stress modality and optimal protocol for imaging at peak stress
- The Tc99 SPECT Profile is being used as a template and the PET-Amyloid Profile as a reference
- After evaluation of GitHub and discussion of its pros and cons, consensus was to proceed with it for the time being
 - The Profile appears as a text document in markdown format and can be transformed to a Word document as needed
 - As additional BC members join and work on the Profile, switching to a different resource may be considered
 - Dr. Lodge will be provided access and user feedback
 - There is an area for adding issues, as well as a forum for recording conversation threads
- 3.1 Site conformance
 - The site accreditation specification was updated from referencing organizations, e.g., ACR, Joint Commission, etc., to "qualified status for clinical trials, e.g., iCROs, etc."
 - Acquisition device specifications were discussed
- Review of Sections 3.3 Product validation and 3.4 Periodic QA to continue during the next call
- Profile will require the use of the Dynamic Cardia Phantom (Data Spectrum Corporation)
- Dynamic scan protocol in Section 4 Assessment Procedures to be fine-tuned by Dr. Moody
- The PET-MBF BC will work on balancing feasibility with technical requirements in the Profile

Next Call: July 11, 2022, at 9 am CT (2nd and 4th Mondays) at 9 am CT

Parties interested in joining the [QIBA LinkedIn](#) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

Process Committee

- **QIBA Process Committee Leaders:** [Kevin O'Donnell, MAsc](#) (Chair) | [Michael Boss, PhD](#) (Co-Chair) <mailto:mboss@acr.org>
- **Wiki Resources:** [Dashboard](#) | [Profiles](#) | [QIBA Profile template](#) | [http://qibawiki.rsna.org/index.php/QIBA_Profile_TemplateHow to Write a QIBA Profile](http://qibawiki.rsna.org/index.php/QIBA_Profile_TemplateHow_to_Write_a_QIBA_Profile) | [http://qibawiki.rsna.org/index.php/How to Write a ProfileClaim Guidance](http://qibawiki.rsna.org/index.php/How_to_Write_a_ProfileClaim_Guidance)
- **Inventory of QIBA tools:** [QIBA LinkedIn page](#) (please join / follow) | [QIBA News](#) | [QIBA Community](#)

- **Other:** [QIBA Webpage](#) | [QIBA Wiki](#) | [QIBA Biomarker Committees](#) | [QIBA Organization Chart](#) | [Dropbox](#)
- **EndNote:** To obtain access to the RSNA EndNote citations, please email: sstanfa@rsna.org.